Navigation Links
Medicare Advantage Open Enrollment Offers One-Time Chance to Change Your Mind: Allsup Outlines Rules for Switching Plans
Date:1/12/2009

January through March, open enrollment helps Medicare recipients make sure they've made the right choice

Belleville, IL (Vocus) January 12, 2009 -- Although annual Medicare enrollment has ended, some Medicare Advantage beneficiaries can still switch their coverage during the current Medicare open enrollment period. That information comes from Allsup, a leading provider of Social Security disability, financial and healthcare-related services to people with disabilities.

"Most people think the Medicare Advantage choice they make during annual enrollment, which runs Nov. 15 to Dec. 31, is written in stone for the next year," said Paul Gada, personal financial planning director and product manager for Allsup Medicare Advisor(SM). "But under certain circumstances, beneficiaries can change their plan by March 31, and they should take advantage of this if they don't think the plan they have is going to best fit their needs." The Allsup Medicare Advisor service helps people with disabilities choose the best, most affordable Medicare plan to meet their specific needs.

During the open enrollment period, Jan. 1 through March 31, some individuals have an opportunity to switch plans, but there are limitations. Specifically, they must continue to keep prescription drug coverage if they had it as of Dec. 31. Or, if they did not have prescription drug coverage as of Dec. 31, they cannot add it to their plan.

For example, someone could switch from a traditional

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Page: 1 2 3 4 5

Related medicine news :

1. Highmark Medicare Services Awarded New Contract from Centers for Medicare & Medicaid Services
2. CMS Selects Palmetto GBA to Administer Medicare Program in Four States
3. National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future
4. George Will Column Misguided in Touting Competitive Bidding as a Medicare Solution; Controversial Bidding Program is Actually Anti-Competitive and Lowers Quality of Care and Access to Care for Seniors and Disabled
5. Medical Clinic Owner Pleads Guilty to Role in $5.3 Million Medicare Fraud Scheme
6. SummaCare Selects Burgess Software As Its Comprehensive Medicare Pricing Solution
7. Massive Cuts to Medicare Home Oxygen Therapy Benefit Taking Effect January 1 Creating Acute Anxiety Among Beneficiary and Provider Communities
8. Miami Physician Sentenced to 30 Years in Prison for $11 Million Medicare Fraud Scheme
9. Allsup Outlines 10 Essential Questions People Need to Ask when Evaluating Medicare Plans
10. Video: Medicare Prescription Drug Benefit Annual Enrollment Period is Halfway Over
11. Prescription Drug Benefits for Medicare Patients with Cancer to Cost More in 2009
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Medicare Advantage Open Enrollment Offers One-Time Chance to Change Your Mind: Allsup Outlines Rules for Switching Plans
Medicare Advantage Open Enrollment Offers One-Time Chance to Change Your Mind: Allsup Outlines Rules for Switching Plans
(Date:7/4/2009)...results, study says , , FRIDAY, July 3...ates scored better than their counterparts in Engl...se of differences in levels of depression and educ...re aggressive treatment for heart disease, a new s...d delayed recall of 10 common nouns, such as tree,...
(Date:7/3/2009)...e to breaking news of drugs reportedly found at th...ociety of Anesthesiologists releases the following...esiologists (ASA), which is made up of , physicia...t know the specific circumstances surrounding Mich...y maintains that Diprivan, or its generic name Pro...
(Date:7/3/2009)...ish knows what it,s like being addicted to prescri...America,s "Other" Drug Problem Prescription Medica... his story of addiction and recovery and how he go...m Center drug and alcohol rehabilitation program...m/09-0703-NarcononMI_72dpi.jpg ) , *(Photo Capti...
(Date:7/3/2009)...iddle age may triple the risk, study shows , ...-aged adults who live alone are twice as likely to...life compared to those who are married or live wit...ong those who are divorced or widowed, according t..., The study included 2,000 men and women in Fin...
Breaking Medicine News(10 mins):Health News:On Memory, Older Americans Outsmart the English 2Health News:American Society of Anesthesiologists Releases Following Statement Related to Media Inquires Regarding Michael Jackson's Death 2Health News:Narconon Graduate Successfully Recovers From Prescription Drug Abuse 2Health News:Living Alone Increases Odds of Developing Dementia 2
...of clot formation inside a coronary stent is three...days, the majority of angioplasties involve placem...oronary artery to keep it open. But the very act o...sel walls and may promote formation of a clot - ir...
...cal industries, Ranbaxy Laboratories and Cipla ann...ay formulation of Ciprofloxacin. The formulation h...dia’s (DCGIs) approval for marketing in India. Cip...pectrum antibiotic. The domestic market for ciprof...
...he liver from damage, according to new research fr...its to laboratory rats. The rats were then given D...ge by interfering with cell synthesis and results ...o obtained the least amount of liver damage.// The...
... adverse effects on the heart among the young and ...s, which have a diameter of less than ten micromet...function, by entering the circulation, especially ...According to a new study by researchers at Harvard...
Other Medicine News:
(Date:6/29/2009)... patients achieved primary and secondary endpoints... -- AcelRx Pharmaceuticals, Inc. today announced p...tudy evaluating the safety and efficacy of its ARX...acute post-operative pain in patients requiring op... placebo, patients receiving ARX-01 Sufentanil Nan...
(Date:6/28/2009)...O, June 29 , - Study Trigge...sei Group Corporation ("Sosei"; TSE Mothers Index:...) announce the commencement of a Phase III,clinic...ong-acting muscarinic,antagonist (LAMA) for the t...,(COPD). NVA237 is a dry powder formulation for or...
(Date:6/26/2009)...oval of New Anti-TNF Therapy in Three Rheumatic Di..., HORSHAM, Pa. and KENILWORTH, N.J., June 26 /PRNe...nd Schering-Plough Corporation (NYSE: SGP ) anno...cts for Human Use (CHMP) of the European Medicines...ding the approval of SIMPONI(TM) (golimumab) as a ...
(Date:6/25/2009)...ighlighted at the College on Problems of Drug Depe... King Pharmaceuticals, Inc. (NYSE:...ting safety and efficacy data for ACUROX(R) and ...rmulations that are in development, at the 71st An...pendence. King is also developing other pain medi...
Breaking Medicine Technology:AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 2AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 3AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 4Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 2Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 3Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 2SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 3SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 4SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 5SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 6SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 7SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 8SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 9SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 10King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 2King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 3King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 4King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 5King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 6Lincare Holdings Inc Announces Fourth Quarter and Year Ended 2008 Financial Results 36155 1Lincare Holdings Inc Announces Fourth Quarter and Year Ended 2008 Financial Results 36155 2Lincare Holdings Inc Announces Fourth Quarter and Year Ended 2008 Financial Results 36155 3Lincare Holdings Inc Announces Fourth Quarter and Year Ended 2008 Financial Results 36155 4Lincare Holdings Inc Announces Fourth Quarter and Year Ended 2008 Financial Results 36155 5Lincare Holdings Inc Announces Fourth Quarter and Year Ended 2008 Financial Results 36155 6Lincare Holdings Inc Announces Fourth Quarter and Year Ended 2008 Financial Results 36155 7Lincare Holdings Inc Announces Fourth Quarter and Year Ended 2008 Financial Results 36155 8Emergency Nurses Association Announces Corporate Sponsors for Leadership Conference 36153 1Emergency Nurses Association Announces Corporate Sponsors for Leadership Conference 36153 2Pharmasset Reports Fiscal First Quarter 2009 Financial Results 10370 1Pharmasset Reports Fiscal First Quarter 2009 Financial Results 10370 2Pharmasset Reports Fiscal First Quarter 2009 Financial Results 10370 3Pharmasset Reports Fiscal First Quarter 2009 Financial Results 10370 4Pharmasset Reports Fiscal First Quarter 2009 Financial Results 10370 5Pharmasset Reports Fiscal First Quarter 2009 Financial Results 10370 6Pharmasset Reports Fiscal First Quarter 2009 Financial Results 10370 7Pharmasset Reports Fiscal First Quarter 2009 Financial Results 10370 8Taking Statins Faithfully Lengthens Life 36144 1Taking Statins Faithfully Lengthens Life 36144 2
....--(BUSINESS WIRE)--Jun 21, 2007 - BioSante,Pharma...on the,Women,s Health Initiative (WHI) Coronary Ar...England Journal of Medicine (NEJM).,The study foun...eceived a standard dose of estrogen therapy had si...the end of the study period,compared with those ta...
... 21, 2007-Novo Nordisk today announced clinical,re...liraglutide -,the once-daily human GLP-1 analogue....utide Effect and Action in Diabetes) programme,and...uately,controlled by two of the most widely used o...ea (glimepiride). All patients in the,study contin...
Other Medicine Technology:New Analysis of WHI Data Shows Reduced Levels of Coronary Artery,Calcification, a Predictor of Cardiovascular Events, in Women aged,50-59 taking Estrogen Therapy 2New Analysis of WHI Data Shows Reduced Levels of Coronary Artery,Calcification, a Predictor of Cardiovascular Events, in Women aged,50-59 taking Estrogen Therapy 3New Analysis of WHI Data Shows Reduced Levels of Coronary Artery,Calcification, a Predictor of Cardiovascular Events, in Women aged,50-59 taking Estrogen Therapy 4Liraglutide provides significantly better glucose control than,insulin glargine in phase 3 study 2Liraglutide provides significantly better glucose control than,insulin glargine in phase 3 study 3Liraglutide provides significantly better glucose control than,insulin glargine in phase 3 study 4
Surgitie&trade Single Use Ligating Loops with Delivery System
Surgitie&trade Single Use Ligating Loops with Delivery System
Surgitie&trade Single Use Ligating Loops with Delivery System
ENDO STITCH&trade Triple-Stitch Single Use Loading Units for use with ENDO Stitch* 10 mm Suturing Device.
Medicine Products: